title: Development of antigen-specific CD8+ CTL in MHC class I-deficient mice through CD4 to CD8 conversion.
abstract: CD8+ CTL are the predominant tumoricidal effector cells. We find, however, that MHC class I-deficient mice depleted of CD8+ T cells are able to mount an effective antitumor immunity after immunization with fused dendritic/tumor cells. Such immunity appears to be mediated by the generation of phenotypic and functional CD8+ CTL through CD4+ to CD8+ conversion, which we have demonstrated at the single cell level. CD4+ to CD8+ conversion depends on effective in vivo activation and is promoted by CD4+ T cell proliferation. The effectiveness of this process is shown by the generation of antitumor immunity through adoptive transfer of primed CD4 T cells to provide protection against tumor cell challenge and to eliminate established pulmonary metastases.
authors.affiliation: Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Shigeo
authors.initials: S
authors.lastname: Koido
authors.forename: Jianchuan
authors.initials: J
authors.lastname: Xia
authors.forename: Masaya
authors.initials: M
authors.lastname: Ohana
authors.forename: Chunlei
authors.initials: C
authors.lastname: Liu
authors.forename: Gregory M
authors.initials: GM
authors.lastname: Cote
authors.forename: Douglas B
authors.initials: DB
authors.lastname: Sawyer
authors.forename: Stuart
authors.initials: S
authors.lastname: Calderwood
authors.forename: Jianlin
authors.initials: J
authors.lastname: Gong
mesh_terms: D019264:Adoptive Transfer; D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology* / Q000637:transplantation; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology*; D019496:Cancer Vaccines; D019070:Cell Lineage / Q000276:immunology*; D015395:Histocompatibility Antigens Class I / Q000235:genetics / Q000276:immunology; D007109:Immunity; D007114:Immunization; D008213:Lymphocyte Activation / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008822:Mice, Transgenic; D013602:T-Lymphocytes, Cytotoxic / Q000166:cytology / Q000276:immunology*
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D015395:Histocompatibility Antigens Class I